For type 2 diabetes mellitus. ANDA 202306, held by Platinum. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 202306 (Metformin Hydrochloride), held by Platinum, was first approved by FDA on Feb 23, 2017, with 4 approved supplements and 0 published complete response letters.
Metformin Hydrochloride Extended-Release Tablets, USP is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 23, 2017 | Original application | Approved |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jul 27, 2026 | Supplement 3Labeling · Standard review | Approved | None posted |
| Aug 27, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 27, 2019 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 23, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters